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Background: The aim of current study was to investigate the way dose is prescribed to lung lesions during SBRT
using advanced dose calculation algorithms that take into account electron transport (type B algorithms). As type A
algorithms do not take into account secondary electron transport, they overestimate the dose to lung lesions. Type
B algorithms are more accurate but still no consensus is reached regarding dose prescription. The positive clinical
results obtained using type A algorithms should be used as a starting point.
Methods: In current work a dose-calculation experiment is performed, presenting different prescription methods. Three
cases with three different sizes of peripheral lung lesions were planned using three different treatment platforms. For each
individual case 60 Gy to the PTV was prescribed using a type A algorithm and the dose distribution was recalculated using
a type B algorithm in order to evaluate the impact of the secondary electron transport. Secondly, for each case
a type B algorithm was used to prescribe 48 Gy to the PTV, and the resulting doses to the GTV were analyzed.
Finally, prescriptions based on specific GTV dose volumes were evaluated.
Results: When using a type A algorithm to prescribe the same dose to the PTV, the differences regarding
median GTV doses among platforms and cases were always less than 10% of the prescription dose. The
prescription to the PTV based on type B algorithms, leads to a more important variability of the median GTV
dose among cases and among platforms, (respectively 24%, and 28%). However, when 54 Gy was prescribed as
median GTV dose, using a type B algorithm, the variability observed was minimal.
Conclusion: Normalizing the prescription dose to the median GTV dose for lung lesions avoids variability
among different cases and treatment platforms of SBRT when type B algorithms are used to calculate the dose.
The combination of using a type A algorithm to optimize a homogeneous dose in the PTV and using a type B
algorithm to prescribe the median GTV dose provides a very robust method for treating lung lesions.Background
The differences between radiotherapy dose calculation
algorithms that take into account the electron transport
phenomenon inside non-homogeneous environments
(category 3&4 or type B) and those that do not (category
1&2 or type A) are well known [1]. The clinical implica-
tions of Monte-Carlo dose calculation algorithms [2,3]
have been described, as well. However, the differences
between type A and type B algorithms for small fields –
with a penumbra region that occupies most of the field
area – depend on many factors, such as lung density,
beam sizes, and the position and size of the target. It is
still not clearly understood how to adapt the protocols* Correspondence: t-lacornerie@o-lambret.fr
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article, unless otherwise stated.based on type A algorithms. Xiao et al. [4] concluded
their study about heterogeneity corrections and RTOG
trial 0236 in 2009 stating “the information provided by
the study will be used for future protocols,”. But almost
3 years later Li et al. stated, about heterogeneities and
the RTOG trial 0813 [5], that “further studies are ex-
pected to establish protocol criteria for MC dose calcula-
tions”. The RTOG trial 0915 requires the use of a type B
algorithm with a PTV edge prescription and an isodose
between 60 and 90% of the dose maximum. That vari-
ability leads to significantly different GTV doses as we
will demonstrate. Many articles have pointed out the
discrepancies between type A and type B algorithms in
this journal [6-8] and in others for many years [9] but
they are almost always focused on results for the PTV.
We believe that the PTV edge prescription is not a goodtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 PDD for 30 mm collimator calculated with Ray-Tracing and Monte-Carlo algorithms in phantom with different densities (left)
on the beam axis (central) and 1 cm off axis (right), GTV (red, density = 1), PTV (blue), lung (green, density = 0.3).
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as will be shown below.
Discrepancies between Monte-Carlo (a type B algorithm)
and Ray-Tracing algorithms (a type A “equivalent path
length” algorithm) were monitored at the beginning of our
experience with Cyberknife (Accuray Inc, Sunnyvale, CA)
five years ago, although the protocol applied to peripheral
lesions for dose prescription was the standard protocol
defined by other teams for: 60 Gy in three fractions
encompassing the PTV [10,11] calculated with type A
algorithms.
Because the Cyberknife has a 6-MV output and no flat-
tening filter, the range of secondary electrons in lung
can be up to 4 cm. In Figure 1, differences between
Ray-Tracing and Monte-Carlo for a 30–mm beam in a
phantom representing a 14-mm peripheral lung lesion
is illustrated. Similar effects between any type A and
type B algorithm can be observed.
Ray-Tracing overestimates the dose in the lung be-
cause it disregards the lack of lateral electronic equilib-
rium and changes of scattered dose. The rebuild-up in
the target observed with Monte-Carlo is ignored by Ray-
Tracing. Behind the rebuild-up zone at the centre of the
target, Ray-Tracing overestimates the dose because ofFigure 2 GTV and PTV for the 3 different lesions analyzed.the absence of scattering in lung tissue. On the edge of
the target, in the PTV margin, the differences are even
more pronounced because the lack of electronic equilib-
rium is dominant in this area, and Ray-tracing applies
the change of density observed on the beam axis
whereas the interface between lung and target is not at
the same depth. The same kind of differences between
every type A and type B algorithm can be observed: they
are maximal in lung at the edge of the PTV (Figure 2).
The smaller the lesion, and the beam, the higher the dis-
crepancy between type A and type B algorithms in lung
[12]. Because of that, modifying the prescription is more
complicated for SBRT than for wide-field RT treating
bigger volumes. Although the dose of 60 Gy is overesti-
mated when calculated by a type A algorithm, local
control has been very high [13], so this actual dose
level should be maintained. Comparison between Pencil
Beam and Collapsed Cone (Oncentra Masterplan, V4.1,
Nucletron Elekta, Veenendaal, Netherlands) for the
Varian Clinac® (Varian Medical Systems Inc., Palo Alto,
CA) and comparison of Pencil-Beam and Monte-Carlo
dose calculations for Novalis® (Brainlab AG, Feldkirchen,
Germany) lead to the same conclusions. Current study
will be applied to these treatment platforms.
Figure 3 Differences (in red) larger than 15 Gy for case 2 on Cyberknife between Ray-Tracing and Monte-Carlo.
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cently published [14] showing a wide variability in
reporting. In the 45 identified studies there were 22 dif-
ferent treatment schemes. One dose level only, probably
PTV based, was reported for each study, ranging from
15 Gy to 72.5 Gy in 1 to 12 fractions. In another paper
van Baardwijk et al. try to determine the best therapeutic
ratio [15] despite the differences between type A and B
algorithms considering only dose at the edge of the
PTV. The questions in these articles will not be an-
swered correctly when considering only the PTV.
Our goal is to establish a consistent dose prescription
and reporting in a heterogeneous environment that is
applicable for different SBRT treatment modalities.
Methods
A dose calculation experiment is proposed to discuss the
different prescription methods. This exercise is not meant
to be an exhaustive demonstration but should primarily
provide a number of arguments to put into perspective
the current prescription methods.
Three different cases with three different sizes of periph-
eral lung lesions (<1 cm, ~2 cm, ~4 cm) were examined
(Figure 3). Each case was calculated with a type A and a
type B algorithm on three different platforms: CyberKnife
with Ray-Tracing and Monte-Carlo (Multiplan v.9.0, 1%
statistical uncertainty and resolution of 1×1×1 mm), Nova-
lis 6 MV with Pencil-Beam and Monte-Carlo (Iplan v.4.1.2,
0.5% statistical uncertainty and resolution of 2×2×1 mm),
and Clinac 6 MV (Varian) with Pencil-Beam and Collapse
Cone (Masterplan v4.0, resolution of 2×2×1 mm). The
PTV was defined as GTV+ 5 mm, for the treatment with
gating or with real-time tracking, details of ballistics are
given in Table 1. The targets were not enlarged for prophy-
lactic treatment (RTOG 0236 & 0915).
Scenario A: 60 Gy was prescribed to 95% of the PTV
using type A algorithms (RTOG 0236). For the Clinac
plans, the margin from PTV to TV was 5 mm, as in
conventional 3D-CRT, consequently the field sizes were
larger than 3×3 cm2 for all cases. The GTV D98% (near
min) and the D50% (median) were compared. Each plan
was recalculated with a type B algorithm while keeping




Novalis (Non-IMRT) 10 copl
oppose
Cyberknife (circular collimators and flattening filter free) 62 non
Clinac (Non-IMRT) prescription like classical 3DRT with type A,
extra-margin from PTV to field edge
5 copla
opposePTV was calculated and again the D98% and D50% for
the GTV were evaluated.
Scenario B: Because type A algorithms overestimate the
delivered dose, 48 Gy instead of 60 was prescribed with
type B algorithms, renormalizing the plans used in Sce-
nario A, to 95% of the PTV, as proposed in the STARS
protocol by the MD Anderson Cancer center. The differ-
ent doses to the GTV were observed for all combinations
of cases and platforms.
Scenario C: Finally, to avoid discrepancies among me-
dian GTV doses, a dose of 54 Gy was prescribed to this
parameter using a type B algorithm. These plans were
first optimized with type A algorithms to ensure a
homogeneous photon fluence in the PTV (−5%, +15% of
prescription dose), recalculated with type B algorithms
and normalized in a way that the GTV D50% equals the
prescription dose (i.e. 54Gy).
Because the three lesions were in the centre of lung, the
doses to organs at risk – esophagus, ribs, and heart – were
very low for all cases; only the normal tissue dose to lung
was recorded. A large number of criteria concerning lung
toxicity have been published [16]. Most of them were cal-
culated for the current study, yet not all of them are pub-
lished here for the sake of brevity. The lung volume
receiving <10 Gy was presented to show that in all scenar-




When prescribing 60 Gy to 95% of the PTV using a type
A algorithm, the maximum discrepancies in the median
dose to the GTV were moderate among studied platforms:
3.6 Gy (6% of the prescription dose (Dp)), and cases:
4.5 Gy (7.5% of Dp) (Table 2). The maximum dose vari-
ance among the nine plans was 6 Gy (10% of Dp), which
is common in SBRT in homogenous tissues. For the GTV
near-minimum dose (D98%), used as proposed by the
ICRU report 83, the maximum differences were compar-
able: 4 Gy (6.7% Dp) among techniques and 2.4 Gy (4%
Dp) among cases. For the two platforms with conventional
stereotactic margins, Novalis and CyberKnife, higher me-
dian doses were obtained for larger lesions. For the ClinacCase 2 Case 3
3.6 cm3 32.8 cm3
14.5 cm3 75.0 cm3
anar and non
d beams
9 coplanar and non
opposed beams
10 coplanar and non
opposed beams
coplanar beams 58 non coplanar beams 52 non coplanar beams
nar and non
d beams
7 coplanar and non
opposed beams
7 coplanar and non
opposed beams
Table 2 Prescription and calculation with type A algorithms (scenario A)
PTV D95% = 60 Gy type A
GTV D98% type A (Gy) GTV D50% type A (Gy) Normal lung receiving less than 10 Gy (cm3)
Case 1 Case 2 Case 3 Case 1 Case 2 Case 3 Case 1 Case 2 Case 3
Novalis 61.5 62.0 61.8 61.6 63.2 64.1 3808 3468 2227
Cyberknife 61.6 64.0 62.3 62.8 64.9 67.3 3799 3488 1992
Clinac 60.7 60.0 60.3 62.3 61.3 64.0 3681 3308 1804
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ventional prescription as for classical 3DRT, the median
dose was almost the same for the three cases.Prescription with type A algorithms and re-calculation
with type B algorithms
When a type B algorithm was used, for each platform,
the PTV D95% was smaller than the prescription dose
according to the type A algorithm (Figure 4). The max-
imum difference was 19.6 Gy (32.7% Dp) (Table 3).
Moreover a large range of doses (40.4–54.4, 23.3% Dp)
was observed. For the GTV D98%, the maximum differ-
ence between cases was 12.4 Gy (20.7% Dp), the max-
imum difference between platforms was 3.6 Gy (6% Dp).
For the GTV D50%, the maximum difference betweenFigure 4 Case 2: GTV DVH for PTV based prescription for the 3 differecases was 13.2 Gy (22%) and the maximum difference
between platforms was 3.2 (5.3%). The differences re-
garding the volume of lung that received less than 10 Gy
for cases 1 and 2 (3% maximum) were small. Type A al-
gorithms overestimated the high dose but the low doses
(<10 Gy) are quite similar.Scenario B
With a prescription of 3x16 Gy to 95% of the PTV using
type B algorithms, the maximum differences for median
doses of the GTV were: 13.4 Gy (28% of the prescription
dose) among the platforms and 11.6 Gy (24.2%) among
cases (Table 4). For GTV D98% (near-min) the maximum
differences were comparable: 7 Gy (14.6%) (Figure 4)
among platforms and 10.1 (21%) among cases (Figure 5).nt platforms (type B algorithms).
Table 3 Calculation with type B algorithms with type A algorithms prescription (scenario A, same monitor units)
PTV D95% = 60 Gy type A
PTV D95% type B (Gy) GTV D98% type B (Gy) GTV D50% type B (Gy) Normal lung receiving less than 10 Gy (cm3)
Case 1 Case 2 Case 3 Case 1 Case 2 Case 3 Case 1 Case 2 Case 3 Case 1 Case 2 Case 3
Novalis 43.7 40.5 52.2 47 47.7 59.4 49.8 53.9 63 3858 3456 2189
Cyberknife 42.7 40.4 49.5 46.3 49.7 55.9 50 57.1 61.5 3824 3537 2090
Clinac 44.6 50.3 54.4 48.7 51.3 58.1 51.4 57 62.1 3757 3259 1817
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ial for more details and additional DVHs (Additional
file 1).
Scenario C
As illustrated above (scenario A), for plans prescribed at
95% of the PTV using type A algorithms, a large range
of GTV50% values was obtained when recalculated using
type B algorithms, Therefore we suggested a prescription
dose of 54 Gy to 50% of the GTV when using a type B
algorithm.
The maximum differences for GTV D98% were 1.8 Gy
(3.4% of the prescription dose) among the platforms and
3.1 Gy (5.8%) among cases (Table 5) Of course with this
scenario there are differences for the PTV D95%, the max-
imum is 9.4 Gy (17% of the prescription dose) among the
platforms and 5.3 Gy (9.7% of the prescription dose)
among cases.
Discussion
The accuracy of Monte Carlo dose calculation for the
studied platforms, Novalis and CyberKnife, has been
demonstrated [18,19] using anthropomorphic phantoms
[20]. Therefore, it is advisable that advanced algorithms
are used to obtain more accurate dose distributions to tar-
gets and organs at risk. The question is how to apply the
well established prescription protocols that lead to positive
clinical results.
On one hand, there are a lot of studies that report excel-
lent local control [11,21,22] with different prescription
schemes in which only the prescription dose to the PTV is
provided without mentioning the algorithm used. On the
other hand, differences between type A and type B algo-
rithms have been observed in many studies [4,5,23,24]
without clear consequences regarding the prescription.
Hurkmans et al. have proposed for the ROSEL study [25]Table 4 Calculation with type B algorithms with prescription
PTV D95% = 48 Gy type B
GTV D98% type B (Gy) GTV D50% type B (G
Case 1 Case 2 Case 3 Case 1 Case 2
Novalis 51.6 56.5 54.6 54.7 63.9
Cyberknife 52.0 59.0 54.2 56.2 67.8
Clinac 52.4 49.0 51.3 55.3 54.4different dose conformity requirements according to
the size of the PTV and the type of the algorithm used.
The prescription dose was the same for all lesions based
on the PTV, but the heterogeneity in the PTV and the
dose constraints for the lung varied according to the size
of the PTV. Van der Voort van Zyp et al. [26] have also
performed a retrospective analysis of Monte-Carlo calcu-
lations on cases treated in their institution. They proposed
three dose levels based on the size of the tumor calculated
with Monte-Carlo and prescribed to the 95% of the PTV
(48 Gy for tumors <3 cm, 51 Gy for tumors of 3–5 cm,
and 54 Gy for tumors >5 cm), which can be considered as
the most consistent proposition to date.
For PTV based prescription using type A algorithms a
small variability for GTV D98% and GTV D50% among
cases, and among platforms was obtained. Recalculation
of the plans using a type B algorithm shows that, there
is a dose escalation according to the size of the GTV
with few discrepancies between the platforms (3.2 Gy,
5.2% of the prescription dose). When a type A algorithm
is used with a PTV based prescription the dose delivered
to the GTV is higher for larger lesions. That may explain
the good local control of all the studies performed using
type A algorithms. This result, also described in detail by
van der Voort van Zyp et al. [26], led to their propos-
ition of the three dose levels.
As the PTV includes a low-density region, lacking elec-
tronic equilibrium, the prescription, using type B algo-
rithms, should not be based on this volume. For example,
the prescription of 48 Gy to the PTV D95% in case 2 leads
to a higher GTV median dose than for case 3 which is a
larger lesion. Even if we prescribed like van der Voort van
Zyp et al. (18) [26] suggest, i.e., 48 Gy to 95% of the PTV
for case 2 and 51 Gy for case 3, the GTV median dose re-
mains inferior to that of case 2 (61.5 Gy vs. 63 Gy for
Novalis, 63.3 Gy vs. 67.8 Gy for CyberKnife). If the sameon PTV (scenario B)
y) Normal lung receiving less than 10 Gy (cm3)
Case 3 Case 1 Case 2 Case 3
57.9 3824 3352 2219
59.6 3777 3446 2218
54.8 3723 3294 1927
Figure 5 Cyberknife: GTV DVH for PTV based prescription for the 3 cases calculated with Monte-Carlo.
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based prescription should not be used.
The PTV is a fictitious volume created to ensure that
the absorbed dose to the target equals the prescription
dose, taking into account positioning uncertainties. Be-
cause of the low density surrounding the GTV, the mini-
mum dose to the PTV is calculated in a low density
region whereas the GTV has a density close to 1.
The PTV D95% depends on the lung density around the
lesion and does not predict the dose to the GTV (28%
variability in the median prescription dose and 14.6% for
Dnear-min for the different treatment devices in our exer-
cise). The difference between PTV D95% and GTV dose
depends on the size of the lesion, lung density, location,
treatment platform and even the operator. Our exercise is
not intended to be exhaustive but only to show that oneTable 5 Calculation with type B algorithms with prescription
GTV D50% = 54 Gy
GTV D98% type B (Gy) PTV D95% type B
Case 1 Case 2 Case 3 Case 1 Case 2
Novalis 51.0 47.8 50.9 47.4 40.6
Cyberknife 50.0 47.0 49.1 46.1 38.2
Clinac 51.2 48.6 50.5 46.9 47.7PTV criterion is not enough to characterize the dose
distribution. The PTV margin in lung can be consid-
ered as the “flash” region margin used for tangential
breast field, where part of the PTV is in air, while it is
not used for prescription. Furthermore the statistical un-
certainty of Monte-Carlo is up to 5% higher (or more for
extreme case of low density lung) in the PTV periphery
than on the GTV median dose (Figure 6) because there
are fewer histories in low density region. With a prescrip-
tion based on the PTV, the discrepancies between treat-
ment systems are much more substantial with type B than
with type A algorithms; 28% vs. 6%.
The best way to avoid these discrepancies among cases
and treatment platforms is to prescribe to the GTV me-
dian dose. The GTV median dose is the most representa-
tive dose, in that the majority of the lesion receives ±5% ofon GTV D50% (scenario C)
Normal lung receiving less than 10 Gy (cm3)
Case 3 Case 1 Case 2 Case 3
44.7 3829 3455 2284
43.5 3794 3563 2309
47.3 3735 3299 1945
Figure 6 Map of % of statistical uncertainties for Monte-Carlo-
Calculation for case 2 and Cyberknife.
Lacornerie et al. Radiation Oncology 2014, 9:223 Page 8 of 10
http://www.ro-journal.com/content/9/1/223the median dose even in the example with the highest de-
gree of heterogeneity: case 2 treated with the CyberKnife.
We believe that the GTV D50% is more relevant than the
GTV near-minimum (D98%) because the GTV encom-
passes sometimes small low density regions, lacking elec-
tronic equilibrium too, so the uncertainty is larger than
for the GTV D50%. However we think we should report
this value.Figure 7 Effect of a shift of the GTV in the envelop of the PTV for cas
GTV shifted within the PTV (blue).During plan optimization the PTV needs to be tar-
geted entirely though, because the GTV can be anywhere
inside the PTV. This task is best achieved using a type A
algorithm, available in all TPSs. In clinical practice, like
in the exercise described in current article, a plan is cre-
ated using a type A algorithm, covering 95% of the PTV
by the prescription isodose. A steep gradient around the
PTV is not really needed, because the effect on the DVH
of the lung is very small and because the CTV exten-
sions are not known, so a relatively homogenous fluence
in the target is maintained. Then a type B algorithm is
used to recalculate and rescale the result and to prescribe
the dose to the GTV median dose (GTV D50%). As the
median does not really depend on the minimum, the GTV
median dose is almost constant no matter where the GTV
is within the PTV envelop and, consequently, is very rep-
resentative of the dose delivered and thus the biological
impact to the tumor. For example if for case 2 treated
with the Cyberknife, where the dose heterogeneity is
largest (difference between PTV D95% and GTV50%
and GTV98%), the GTV is shifted 5 mm towards the
dose minimum in the PTV (overriding density of PTV-
GTV and GTV shifted), (see Figure 7), the median dose to
the GTV is 53.2 Gy instead of 54 Gy (a 1.5% variation):
because of the rebuild-up effect the isodose moves with
the GTV. For all other studied situations the variation
would be lower because the dose heterogeneity is lower
within the PTV. The combination of optimizing to the
PTV using a type A algorithm, and prescribing to the me-
dian GTV dose using a type B algorithm is thus a very ro-
bust method.
The reoptimization with type B algorithms, studied in
this article, is not described because it increases uncertain-
ties of delivered dose. To compensate the lack of elec-
tronic equilibrium the system will increase the fluence ine 2 and Cyberknife: The red contour indicates the position of the
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GTV will be overexposed when it moves into the re-
gions with increased photon fluence. As in all situations
of lack of electronic equilibrium, like superficial neck
nodes in build-up region, optimization increases the
uncertainty on the delivered dose. New algorithms tak-
ing into account 4DCT and uncertainty of patient pos-
ition should be used to have a robust optimization. As
this robust optimization algorithms are not yet available
in our TPSs, the method proposed in current work (op-
timizing on the PTV using a type A algorithm followed
by recalculation using a type B algorithm) provides the
best available alternative for the moment.
In this experiment, the breathing motion was consid-
ered controlled. If the PTV is defined from an ITV which
includes all the positions of the GTV during the breathing
cycle, the beam sizes used were larger so the lack of lateral
electronic equilibrium was smaller but, still, the PTV
D95% did not predict the minimum dose to the GTV, be-
cause the PTV margin consisted mostly of a low-density
region. Therefore, also for the ITV method, we think it is
better to prescribe to the GTV median. Without any gat-
ing or real-time tracking, the dose calculation is only a
snapshot, but even then prescribing to the GTV D50% is
more precise because it takes into account the rebuild-
up. Actually the larger the margin the larger the differ-
ence between PTV minimum and GTV dose. That
means that a large uncertainty in GTV position leads to a
higher delivered dose. A GTV based prescription avoids
this drawback.
Conclusion
The right dose needed for lung lesions treated by SBRT
is not yet known. Advanced algorithms are needed and
the GTV dose should be reported because the PTV pre-
scription does not predict the dose to the GTV. Every
team should report GTV D50% and D98% to enable a
comparison of all results.
We suggest using type A algorithms to target the PTV
during optimization and to recalculate dose with type B
algorithms rescaling the prescription to the GTV median
dose. Until robust optimization algorithms will be intro-
duced in all TPSs, this appears to be the most robust
way to avoid discrepancies from device to device and
case to case and this with or without motion manage-
ment (tracking, gating).
Additional file
Additional file 1: Slideshow.
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